At the Forefront of Targeted Cancer Therapies
Developing the next generation of medications for the treatment of cancers and genetic diseases
Active Clinical Development Programs
Bimiralisib’s oral and topical formulations are under clinical development for the treatment of Head and Neck Squamous Cell Carcinoma (oral) and Cutaneous T-Cell Lymphoma (topical).
In addition, PIQUR has several other compounds in preclinical research in oncology, dermatology, CNS disorders and genetic diseases.
Clinical Development
Pre-clinical
Partners
To fully exploit the potential of our drug candidates, we welcome strategic partnerships with renowned biotech and pharmaceutical companies.
Investors
PIQUR Therapeutics AG is a privately owned company backed by private investors and Versant Venture, a leading venture capital firm.
Career Development
We are always looking to develop our team. Our location and facilities are an ideal place for you to be at the forefront of cancer therapy discoveries.